Sumimasa Nagai

561 total citations
27 papers, 196 citations indexed

About

Sumimasa Nagai is a scholar working on Oncology, Economics and Econometrics and Physiology. According to data from OpenAlex, Sumimasa Nagai has authored 27 papers receiving a total of 196 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Economics and Econometrics and 7 papers in Physiology. Recurrent topics in Sumimasa Nagai's work include Biomedical Ethics and Regulation (7 papers), Health Systems, Economic Evaluations, Quality of Life (5 papers) and Pharmaceutical Economics and Policy (5 papers). Sumimasa Nagai is often cited by papers focused on Biomedical Ethics and Regulation (7 papers), Health Systems, Economic Evaluations, Quality of Life (5 papers) and Pharmaceutical Economics and Policy (5 papers). Sumimasa Nagai collaborates with scholars based in Japan, United States and Italy. Sumimasa Nagai's co-authors include Keiya Ozawa, Keiya Ozawa, Mineo Kurokawa, Akira Hangaishi, Zaina P. Qureshi, Charles L. Bennett, Yoshinobu Kanda, Hiroyuki Satō, Toru Motokura and Kumi Oshima and has published in prestigious journals such as Blood, Oncogene and The Lancet Oncology.

In The Last Decade

Sumimasa Nagai

25 papers receiving 194 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sumimasa Nagai Japan 8 66 59 45 42 39 27 196
André Vicente Esteves de Carvalho Brazil 12 35 0.5× 46 0.8× 222 4.9× 32 0.8× 22 0.6× 34 319
Katherine Armour Australia 8 37 0.6× 20 0.3× 165 3.7× 14 0.3× 14 0.4× 12 267
Giovanna Malara Italy 12 43 0.7× 22 0.4× 231 5.1× 18 0.4× 65 1.7× 26 347
Pawinee Kupatawintu Thailand 10 22 0.3× 18 0.3× 99 2.2× 29 0.7× 78 2.0× 34 307
Ofelia Baniandrés Spain 9 33 0.5× 23 0.4× 163 3.6× 13 0.3× 60 1.5× 34 274
JC Prinz Germany 10 41 0.6× 31 0.5× 372 8.3× 23 0.5× 67 1.7× 10 442
Roos Netherlands 6 50 0.8× 12 0.2× 40 0.9× 140 3.3× 12 0.3× 11 349
Mardiah Suci Hardianti Indonesia 10 99 1.5× 10 0.2× 48 1.1× 88 2.1× 14 0.4× 55 315
Ena Singh United States 7 41 0.6× 119 2.0× 235 5.2× 43 1.0× 6 0.2× 7 323
Alex Kudrin United Kingdom 10 56 0.8× 57 1.0× 215 4.8× 47 1.1× 43 1.1× 14 309

Countries citing papers authored by Sumimasa Nagai

Since Specialization
Citations

This map shows the geographic impact of Sumimasa Nagai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sumimasa Nagai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sumimasa Nagai more than expected).

Fields of papers citing papers by Sumimasa Nagai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sumimasa Nagai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sumimasa Nagai. The network helps show where Sumimasa Nagai may publish in the future.

Co-authorship network of co-authors of Sumimasa Nagai

This figure shows the co-authorship network connecting the top 25 collaborators of Sumimasa Nagai. A scholar is included among the top collaborators of Sumimasa Nagai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sumimasa Nagai. Sumimasa Nagai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kunita, Akiko, Miho Ogawa, Sumimasa Nagai, et al.. (2025). Cyclin E1 overexpression sensitizes ovarian cancer cells to WEE1 and PLK1 inhibition. Oncogene. 44(19). 1375–1386. 1 indexed citations
2.
Shinohara, K, et al.. (2025). Regulatory Approval of CAR‐T Cell and BsAb Products for Lymphoid Neoplasms in the US, EU, and Japan. Clinical Pharmacology & Therapeutics. 118(1). 118–127.
3.
Nagai, Sumimasa, et al.. (2024). Characteristics of Drugs from Non‐Global Companies for Hematologic Malignancies and Impact on Global Regulatory Approval. Clinical Pharmacology & Therapeutics. 117(1). 232–239. 1 indexed citations
4.
5.
Nagai, Sumimasa, Hiroshi Nishihara, Takayoshi Suzuki, et al.. (2022). Recommendations related to the analytical equivalence assessment of gene panel testing. Cancer Science. 113(10). 3282–3290. 1 indexed citations
6.
Nagai, Sumimasa. (2021). Regulatory hurdles for CAR T-cell therapy in Japan. The Lancet Haematology. 8(10). e686–e687. 3 indexed citations
7.
Nagai, Sumimasa. (2020). [Pharmaceutical approval process of drugs for hematological malignancies: current situations in Japan].. PubMed. 61(5). 437–444. 1 indexed citations
8.
Nagai, Sumimasa & Daisuke Sugiyama. (2018). Current Trends in Clinical Development of Gene and Cellular Therapeutic Products for Cancer in Japan. Clinical Therapeutics. 41(1). 174–184.e3. 3 indexed citations
9.
10.
Qureshi, Zaina P., Sumimasa Nagai, & Charles L. Bennett. (2018). Biosimilar Filgrastim Use in the United States vs the European Union and Japan—Why Does It Lag Behind and What Can Be Done?. JAMA Oncology. 5(3). 297–297. 7 indexed citations
11.
Nagai, Sumimasa & Keiya Ozawa. (2017). New Japanese Regulatory Frameworks for Clinical Research and Marketing Authorization of Gene Therapy and Cellular Therapy Products. Current Gene Therapy. 17(1). 17–28. 11 indexed citations
12.
Nagai, Sumimasa & Keiya Ozawa. (2016). Comprehensive analysis of clinical development and regulatory submission promotion schemes for oncologic drugs as the Japanese national projects. Investigational New Drugs. 34(6). 777–791. 1 indexed citations
13.
Yang, Y. Tony, Sumimasa Nagai, Brian Chen, et al.. (2016). Generic oncology drugs: are they all safe?. The Lancet Oncology. 17(11). e493–e501. 27 indexed citations
14.
Nagai, Sumimasa & Keiya Ozawa. (2016). Regulatory approval pathways for anticancer drugs in Japan, the EU and the US. International Journal of Hematology. 104(1). 73–84. 10 indexed citations
15.
Nagai, Sumimasa & Keiya Ozawa. (2016). Clinical trial designs to obtain marketing authorization of drugs for haematological malignancy in Japan, the EU and the US. British Journal of Haematology. 174(2). 249–254. 4 indexed citations
16.
Nagai, Sumimasa, Tsuyoshi Takahashi, & Mineo Kurokawa. (2010). The Impact of Molecularly Targeted Therapies Upon the Understanding of Leukemogenesis and the Role of Hematopoietic Stem Cell Transplantation in Acute Promyelocytic Leukemia. Current Stem Cell Research & Therapy. 5(4). 372–378. 6 indexed citations
17.
Nagai, Sumimasa, Tsuyoshi Takahashi, & Mineo Kurokawa. (2009). Beneficial and Adverse Effects of Molecularly Targeted Therapies for Acute Promyelocytic Leukemia in Central Nervous System. CNS & Neurological Disorders - Drug Targets. 8(5). 387–392. 1 indexed citations
18.
Nagai, Sumimasa, Yasuhito Nannya, Akira Hangaishi, Tsuyoshi Takahashi, & Mineo Kurokawa. (2009). The race and dose of chemotherapy should be considered for optimizing maintenance therapy for acute promyelocytic leukemia. Leukemia Research. 33(10). 1427–1429. 2 indexed citations
19.
Nagai, Sumimasa, Motoshi Ichikawa, Tsuyoshi Takahashi, et al.. (2007). The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia. Experimental Hematology. 35(11). 1747–1752. 24 indexed citations
20.
Oshima, Kumi, Yoshinobu Kanda, Yuki Asano‐Mori, et al.. (2007). Presumptive treatment strategy for aspergillosis in allogeneic haematopoietic stem cell transplant recipients. Journal of Antimicrobial Chemotherapy. 60(2). 350–355. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by André Vicente Esteves de Carvalho Breakdown of academic impact, for papers by Katherine Armour Breakdown of academic impact, for papers by Giovanna Malara Breakdown of academic impact, for papers by Pawinee Kupatawintu Breakdown of academic impact, for papers by Ofelia Baniandrés Breakdown of academic impact, for papers by JC Prinz Breakdown of academic impact, for papers by Roos Breakdown of academic impact, for papers by Mardiah Suci Hardianti Breakdown of academic impact, for papers by Ena Singh Breakdown of academic impact, for papers by Alex Kudrin
Rankless by CCL
2026